Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Chronic Kidney Failure
99%
Albuminuria
71%
Dapagliflozin
66%
Placebo
61%
Creatinine
61%
Kidney Disease
50%
Clinical Trial
41%
Sodium Glucose Cotransporter 2 Inhibitor
39%
Diabetic Nephropathy
39%
Canagliflozin
37%
Heart Failure
25%
Kidney Failure
24%
End Stage Renal Disease
20%
Biological Marker
19%
Atrasentan
17%
Diabetes Mellitus
15%
Disease Exacerbation
15%
Randomized Controlled Trial
14%
Angiotensin Receptor Antagonist
14%
Cardiovascular Disease
14%
Renin
14%
Empagliflozin
13%
Angiotensin
12%
Hemoglobin A1c
11%
Cardiovascular Risk
11%
Adverse Outcome
11%
Adverse Event
10%
Endothelin Receptor Antagonist
10%
Non Insulin Dependent Diabetes Mellitus
9%
Disease
9%
Glucagon Like Peptide 1 Receptor Agonist
9%
Aldosterone
8%
Losartan
8%
Microalbuminuria
8%
All Cause Mortality
7%
Proteinuria
7%
Sodium Glucose Cotransporter 2
7%
Finerenone
7%
Randomized Clinical Trial
7%
Congestive Heart Failure
6%
Maturity Onset Diabetes of the Young
6%
Controlled Clinical Trial
6%
Mineralocorticoid Antagonist
6%
Dipeptidyl Carboxypeptidase Inhibitor
6%
Immunoglobulin A Nephropathy
6%
Brain Natriuretic Peptide
6%
Irbesartan
6%
Albumin
5%
Combination Therapy
5%
Medicine and Dentistry
Chronic Kidney Disease
81%
Maturity Onset Diabetes of the Young
62%
Cardiovascular System
56%
Albuminuria
55%
Glomerular Filtration Rate
52%
Nephropathy
46%
Placebo
39%
Creatinine
37%
Canagliflozin
36%
Diabetes
35%
Patient with Type 2 Diabetes
34%
Diabetic Nephropathy
32%
Urinary System
31%
Clinical Trial
30%
Dapagliflozin
29%
Sodium Glucose Cotransporter 2 Inhibitor
29%
Kidney Function
27%
Renal Failure
21%
Biological Marker
21%
Post-Hoc Analysis
20%
Heart Failure
20%
Meta-Analysis
19%
Cardiovascular Disease
19%
End Stage Renal Disease
18%
Disease Exacerbation
15%
Hazard Ratio
14%
Diabetes Mellitus
14%
Blood Pressure
13%
Renin Angiotensin Aldosterone System
11%
Randomized Controlled Trial
11%
Cardiovascular Risk
10%
Proteinuria
10%
Treatment Effect
10%
Hemoglobin A1c
9%
Microalbuminuria
8%
Renal Protection
8%
Disease
7%
Adverse Outcome
7%
Systolic Blood Pressure
7%
Angiotensin Receptor Antagonist
7%
Sodium Intake
7%
Adverse Event
7%
Empagliflozin
6%
Immunoglobulin A Nephropathy
6%
Sodium Glucose Cotransporter 2
6%
Proportional Hazards Model
6%
Glucagon-Like Peptide-1 Agonist
5%
Randomized Clinical Trial
5%
Patient with Diabetes
5%
Congestive Heart Failure
5%
Keyphrases
Chronic Kidney Disease
72%
Albuminuria
52%
Type 2 Diabetes Mellitus (T2DM)
48%
Dapagliflozin
46%
Type 2 Diabetic Patients
42%
Albumin-to-creatinine Ratio
35%
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
35%
Estimated Glomerular Filtration Rate
32%
Canagliflozin
31%
Diabetic Kidney Disease
30%
Placebo
28%
Kidney Outcomes
21%
Cardiovascular Outcomes
21%
Confidence Interval
18%
Diabetes
18%
Clinical Trials
17%
Kidney
16%
Meta-analysis
15%
Hazard Ratio
15%
Kidney Failure
14%
Kidney Disease Progression
14%
Nephropathy
14%
Credence
11%
Renal Events
11%
Renal Outcome
10%
Kidney Function
10%
Atrasentan
10%
Adverse Outcomes
10%
Cardiovascular Mortality
10%
Diabetic Nephropathy
9%
Clinical Evaluation
9%
Angiotensin Receptor Blockers
9%
Heart Failure
8%
Kidney Disease
8%
Treatment Effect
8%
Randomized Controlled Trial
8%
Risk Markers
8%
Empagliflozin
7%
Patients with Diabetes
7%
Glomerular Filtration Rate
7%
Blood Pressure
7%
Proteinuria
7%
Randomized Placebo-controlled Trial
7%
Urinary Albumin Excretion
6%
Estimated Glomerular Filtration Rate Decline
6%
Endothelin Receptor Antagonist
6%
Evaluation Trial
6%
Systolic Blood Pressure
6%
Hemoglobin A1c (HbA1c)
6%
Safety Outcomes
6%
